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Joseph P. Archie, MD, Raleigh, NC
This prospective randomized trial supports the conclusions of
most other similar studies indicating that the perioperative and
midterm stroke and mortality rates for saphenous vein–patched
and synthetic-patched carotid endarterectomy (CEA) are similar
and low. It raises controversy concerning the management of
severe recurrent stenosis, the value of ultrasound surveillance after
CEA, and the importance of the statistically significantly higher
rate of moderate (50%) and severe (70%) recurrent stenosis
with Dacron-patched CEA compared with vein-patched CEA. The
authors’ indication for intervention in high-grade recurrent steno-
sis is development of ipsilateral symptoms. While their protocol
allows for a superb natural history study of CEA, for which they are
to be congratulated, it also negates the issue of the value of
follow-up duplex scanning. On the basis of the observation that
none of 11 patients in whom greater than 70% recurrent stenosis
developed had symptoms, they recommend not performing serial
ultrasound surveillance after CEA. Although it is well known that
the incidence of stroke due to early and midterm recurrent stenosis
is low, the risk of repeat intervention may be significantly lower.
Eleven patients with recurrent stenosis is too small a number to
hang one’s hat on, particularly given the 95% confidence interval of0% to 26% for observing no events in 11 samples (binomial
distribution). The 7.1% rate of greater than 70% recurrent
stenosis and the 12.4% rate of greater than 50% recurrent
stenosis at 3 years reported in this study for Dacron-patched
CEA are similar to what others have found. These 3-year rates
only partially reflect what may occur later, when the major
component of recurrent disease is atherosclerotic, not the ear-
lier and more benign hyperplasia. Even though only 12% of the
patients in this trial were operated on because of asymptomatic
stenosis, it would be difficult for me not to offer serial ultra-
sound surveillance to patients operated on to treat asymptom-
atic stenosis and who received the Dacron patch. Further, if I
had a high-grade carotid stenosis, I probably would not agree to
receive a Dacron patch if I knew the moderate to severe recur-
rence rate was 7% to 12% in 3 years.
These somewhat biased comments aside, this trial emphasizes
the need to clearly determine whether detection of asymptomatic
recurrent stenosis after CEA (or after carotid angioplasty with
stenting) and repeat intervention is of value in stroke prevention.
Perhaps only certain subsets of patients may benefit from ultra-
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